-

$

,

.

9

8

7

6

5

4

3

2

1

0

-

$

,

.

9

8

7

6

5

4

3

2

1

0

-

$

,

.

Why Robinhood?

You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!

About

Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

Collections

Technology

Health

Pharmaceutical

Therapy

Medical

Biotechnology

Manufacturing

2014 IPO

News

Yahoo FinanceMay 7

Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy?

While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Revance Therapeutics, Inc. (NASDAQ:RVNC) due to its excellent fundamentals in more than one area. RVNC is a company with strong financial health as well as an optimistic future outlook. Below, I've touched on some key aspects you should know on a high level. For those int...

131

Yahoo FinanceMay 1

Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know

Wall Street expects a year-over-year increase in earnings on higher revenues when Revance Therapeutics (RVNC) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

65

Price Paid on Robinhood

37% Lower

Right Now

52 Week Low

$10.51

Average Price Paid

$18.32

52 Week High

$32.45

Earnings

-$1.12

-$0.98

-$0.85

-$0.71

Q3 2017

Q4 2017

Q1 2018

Q2 2018

Q3 2018

Q4 2018

Q1 2019

Q2 2019

Estimated

—

Actual

Expected Aug 1, After Hours

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy RVNC

Shares

Market Price$11.61

Commissions$0.00

Sign up for a Robinhood Account to buy or sell RVNC stock and options commission-free.